Добавил:
Sekretar
kiopkiopkiop18@yandex.ru
t.me/Prokururor I Вовсе не секретарь, но почту проверяю
Опубликованный материал нарушает ваши авторские права? Сообщите нам.
Вуз:
Предмет:
Файл:Ординатура / Хирургия / Библиотека им академика М.И. Перельмана / Книга_212_библиотеки_им_акад_М_И_Перельмана
.pdf
201
136. Mi, E. Z. Comparative study of endoscopic surveillance in hereditary diffuse
gastric cancer according to CDH1 mutation status / E.Z. Mi, M. di Pietro // Gastrointest.
Endosc. – 2018. – Vol. 87 (2). – P. 408–18.
137. Milano, A. F. 20–Year Comparative Survival and Mortality of Cancer of the
Stomach by Age, Sex, Race, Stage, Grade, Cohort Entry Time–Period, Disease Duration
& Selected ICD–O–3 Oncologic Phenotypes: A Systematic Review of 157,258 Cases for
Diagnosis Years 1973–2014: (SEER*Stat 8.3.4) / A.F. Milano // J Insur Med. – 2019. –
Vol. 48(1). – P. 5–23.
138. Mitra, R. SFSS Class: an integrated approach for miRNA based tumor
classification / R. Mitra // BMC Bioinform. – 2010. – V. 1. – P. 31–38.
139. Miyazawa, M. Gastric adenocarcinoma of fundic gland type: Five cases
treated with endoscopic resection / M. Miyazawa // World J Gastroenterol. – 2015. – Vol.
21(26). – P. 8208–8214. – URL: https://doi.org/10.3748/wjg.v21.i26.8208 (Accessed:
14.11.2023).
140. MLH1 Promoter Methylation and Prediction/Prognosis of Gastric Cancer: A
Systematic Review and Meta and Bioinformatic Analysis / S. Shen, X. Chen, H. Li H.,
[et al.] // J Cancer. – 2018. – Vol. 9(11). – P. 1932–1942.
141. Nakamura, J. Methylationmediated gene silencing as biomarkers of gastric
cancer: a review / J. Nakamura J. // World J Gastroenterol. – 2014. – Vol. 20. – P. 11991–
12006.
142. New insights into the inflamed tumor immune microenvironment of gastric
cancer with lymphoid stroma: from morphology and digital analysis to gene expression /
I. Gullo, P. Oliveira, M. Athelogou M., [et al.] // Gastric Cancer. – 2019. – Vol. 22(1). –
P. 77–90. – doi.org/10.1007/s10120–018–0836–8.
143. Nishizawa, T. The role of microRNA in gastric malignancy / T. 116 /
T. Nishizawa // Int. J. Mol. Sci. –2013. – Vol. 14 (5). – P. 9487–9496.
144. Nurgalieva, А. Whole Exome Sequencing Study Suggests an Impact of
FANCA, CDH1 and VEGFA Genes on Diffuse Gastric Cancer Development / A.
Nurgalieva // Genes (Basel). – 2023. – Vol. 14(2). – P. 280.
https://t.me/med1917
202
145. OLGA staging for gastritis: a tutorial // Dig Liver Dis. – 2008. – Vol. 40. –
№8. – P. 650–658.
146. Oliveira, C. Familial gastric cancer: genetic susceptibility, pathology, and
implications for management / C. Oliveira // Lancet Oncol. – 2015. – Vol. 16. – P. 60–
70.
147. Ooi, A. Predominant paneth cell differentiation in an intestinal type gastric
cancer / A. Ooi // Pathol Res Pract. – 1991. – Vol. 187(2–3). – P. 220–225. – URL:
https://doi.org/10.1016/s0344–0338(11)80775–2 (Accessed: 14.11.2023).
148. Overview on new progress of hereditary diffuse gastric cancer with CDH1
variants / M.N. Hu, S.H. Hu, X.W. Zhang, [et al.] // Tumori. – 2020. – 106(5). – P. 346–
355. – doi: 10.1177/0300891620949668.
149. Palanisamy, N. Rearrangements of the RAF kinase pathway in prostate
cancer, gastric cancer and melanoma / N. Palanisamy // Nat Med. – 2010.– Vol. 16. – P.
793–798.
150. Paoletti, X. Benefit of adjuvant chemotherapy for resectable gastric cancer:
A meta–analysis / X. Paoletti // JAMA. – 2010. – P. 1729– 1737.
151. Pathology and prognosis of gastric carcinoma: well versus poorly
differentiated type / Y. Adachi, K. Yasuda, M. Inomata M. [et al.] // Cancer. – 2000. –
Vol. 89(7). – P. 1418–1424.
152. Pattern of clinically relevant mutations in consecutive series of Russian
colorectal cancer patients / G. Yanus, A. Belyaeva, A. Ivantsov A. [et al.] // Med oncol.
– 2013 – Vol. 30 (3). – P. 686.
153. Polakis, P. Wnt signaling in cancer / P. Polakis // Cold Spring Harb Perspect
Biol. – 2012. – Vol. 4. – P. 32–42.
154. Preexisting oncogenic events impact trastuzumab sensitivity in ERBB2–
amplified gastroesophageal adenocarcinoma / J. Kim, C. Fox, S. Peng, [et al.] // J Clin
Invest. – 2014. – Vol. 124. – P. 5145–5158.
155. Promoter Methylation Frequency in Colorectal Cancer Patients and Related
Clinicopathological and Molecular Features / X. Li, X. Yao, Y. Wang, [et al.] // PLoS
One. – 2013. – V.8. – P. 12–18.
https://t.me/med1917
203
156. Qiao, Y.Q. Risk factors for surgical–site infections after radical gastrectomy
for gastric cancer: a study in China / Y.Q. Qiao // Chin Med J (Engl). – 2020. – Vol.
133(13). – P. 1540–1545.
157. Quantitative weighting of postoperative complications based on the
accordion severity grading system: Demonstration of potential impact using the American
college of surgeons national surgical quality improvement program / M.R. Porembka,
B.L. Hall, M. Hirbe, S.M. Strasberg // J. Am. Coll Surg. – 2010. – Vol. 210, № 3. – P.
286–298.
158. Rawla, P. Epidemiology of gastric cancer: global trends, risk factors and
prevention / P. Rawla, A. Barsouk // Prz Gastroenterol. – 2019. – Vol. 14(1). – P. 26–38.
159. Regulatory crosstalk between lineage–survival oncogenes KLF5, GATA4
and GATA6 cooperatively promotes gastric cancer development / N.Y. Chia, N. Deng,
K. Das [et al.] // Gut. – 2015. – Vol. 64. – P. 707–719.
160. Rehm, M. Das Stewart–Modell. «Moderner» Ansatz zur Interpretation des
Säure–Basen–Haushalts. The Stewart model. «Modern» approach to the interpretation of
the acid–base metabolism / M. Rehm // Anaesthesist. – 2004. – Vol. 53(4). – P. 347–57.
161. Rokutan, H. Comprehensive mutation profiling of mucinous gastric
carcinoma / H. Rokutan // J Pathol. – 2016. – Vol. 240(2). – P. 137–148. – URL:
https://doi.org/10.1002/path.4761 (Accessed: 14.11.2023).
162. Role of hMLH1 and E–cadherin promoter methylation in gastric cancer
progression / M. Moghbeli, O. Moaven B. Memar, [et al.] // Journal of gastrointestinal
cancer. – 2014. – Vol. 45. – P. 40–7.
163. Rosenfeld, N. MicroRNAs accurately identify cancer tissue origin / N.
Rosenfeld // Nat Biotechnol. – 2008. – Vol. 26 (4). – P. 462–9.
164. Sadeghi, M. Cancer cachexia: Diagnosis, assessment, and treatment / M.
Sadeghi // Crit Rev Oncol Hematol. – 2018. – Vol. 127. – P. 91–104.
165. Saito, S. A clinicopathological and immunohistochemical study of gastric
cancer with squamous cell carcinoma components: a clinically aggressive tumor / S. Saito
// J Dig Dis. – 2012. – Vol. 13(8). – P. 407–413. – URL: https://doi.org/10.1111/j.1751–
2980.2012.00610.x (дата обращения: 14.11.2023).
https://t.me/med1917
204
166. Satava, R. M. Identification and reduction of surgical error using simulation
/ R. M. Satava // Min. Invas. Therapy Allied Technol. – 2005. – Vol. 14, № 4–5. – P.
257–261.
167. Screening for gastric cancer in Asia: current evidence and practice / W.K.
Leung, M. Wu, Y. Kakugawa, [et al.] // Lancet. Oncol. – 2008. – Vol. 9. – № 3. – P.
279287.
168. Sekar, D. Significance of microRNA–21 in gastric cancer / Sekar, D. R.
Krishnan, K. Thirugnanasambantham // Clin Res Hepatol Gastroenterol. – 2016. –Vol 40.
– №5. – P. 538–545.
169. Shenoy, S. CDH1 (E–Cadherin) Mutation and Gastric Cancer: Genetics,
Molecular Mechanisms and Guidelines for Management / S. Shenoy // Cancer Manag
Res. – 2019. – Vol. 13(11). – P. 10477–10486. -– doi: 10.2147/CMAR.S208818.
170. Smyth, E.C. Effect of pathologic tumor response and nodal status on survival
in the medical research council adjuvant gastric in fusional chemotherapy trial / E.C.
Smyth // J Clin Oncol. – 2016. – Vol. 34(23). – P. 2721–2727. –
https://doi.org/10.1200/jco.2015.65.7692.
171. Smyth, E.C. Gastric cancer / E.C. Smyth // Lancet. – 2020. – Vol.
396(10251). – P. 635–648.
172. Stanta, G. Guidelines for Molecular Analysis in Archive tissues / G. Stanta
// springer Berlin Heidelberg. – 2011. – P. 323.
173. Strasberg, S. M. The accordion severity grading system of surgical
complications / S.M. Strasberg, D.C. Linehan, W.G. Hawkins // Ann. Surg. – 2009. –
Vol. 250. – № 2. – P. 177–186.
174. Sulahian, R. An integrative analysis reveals functional targets of GATA6
transcriptional regulation in gastric cancer / R. Sulahian // Oncogene. – 2014. – Vol. 33.
– P. 5637–5648.
175. Sumiyama, K. Past and current trends in endoscopic diagnosis for early-stage
gastric cancer in Japan / K. Sumiyama // Gastric Cancer. – 2017. – Vol. 20. – P. 20–27.
176. Sung, H. Global cancer statistics 2020: GLOBOCAN estimates of incidence
and mortality worldwide for 36 cancers in 185 countries / H. Sung // CA Cancer J Clin. –
https://t.me/med1917
205
2021. – Vol. 71. – P, 209– 249. – URL: https://doi.org/10.3322/caac.21660 (Accessed:
14.11.2023).
177. Takahashi, N. Clinicopathological features and prognostic roles of KRAS,
BRAF, PIK3CA and NRAS mutations in advanced gastric cancer / N. Takahashi,
Y. Yamada, H. Taniguchi H. // BMC Res Notes. – 2014. – Vol. 7. – P. 271.
178. Tan, I.B. Intrinsic subtypes of gastric cancer, based on gene expression
pattern, predict survival and respond differently to chemotherapy / I.B. Tan, T. Ivanova,
K.H. Lim // Gastroenterology. – 2011. – Vol. 14. – P. 476–85.
179. Tao, J. CD44–SLC1A2 gene fusions in gastric cancer / J. Tao, N.T. Deng,
K. Ramnarayanan // Sci Transl Med. – 2011. – Vol. 3. – P. 24–29.
180. The clinicopathological significance of CDH1 in gastric cancer: a meta–
analysis and systematic review / W. Zeng, J. Zhu, L. Shan, [et al.] // Drug Des Devel
Ther. – 2015. – Vol. 9. – P. 2149–57. – doi: 10.2147/DDDT.S75429.
181. The WHO Classification of Tumours Editorial Board. Digestive system
tumours. WHO classification of tumours vol. 1. 5th ed. – Lyon, France: IARC, 2019. –
635 p.
182. Tie, J. MiR–218 inhibits invasion and metastasis of gastric cancer by
targeting the Robo1 receptor / J. Tie. – PLoS Genet, 2010. – 428 p.
183. Ushiku, T. SALL4 represents fetal gut differentiation of gastric cancer, and
is diagnostically useful in distinguishing hepa–toid gastric carcinoma from hepatocellular
carcinoma / T. Ushiku // Am J Surg Pathol. – 2010. – Vol. 34(4). – P. 533–540. – URL:
https://doi.org/10.1097/PAS.0b013e3181d1dcdd (Accessed: 14.11.2023).
184. Viable Mononuclear Cell Stability Study for Implementation in a
Proficiency Testing Program: Impact of Shipment Conditions / O. Kofanova, K. Davis,
B. Glazer, [et al.] // Biopreservation and Biobanking. – 2014. – Vol. 12 (3). – P. 206–16.
185. Wang, J. J. Jiang, miR–30 functions as an oncomiR in gastric cancer cells
through regulation of P53–mediated mitochondrial apoptotic pathway, Biosci / J.J. Wang,
L.M. Y. Jiao, L.L. Cui // Biotechnol. Biochem. – 2017. – Vol. 81 (1). – P. 119–126.
https://t.me/med1917
206
186. Wang, K. Whole–genome sequencing and comprehensive molecular
profiling identify new driver mutations in gastric cancer / K. Wang, S.T. Yuen, J. Xu //
Nat Genet. – 2014. – Vol. 46. – P. 573–582.
187. Wang, K. Exome sequencing identifies frequent mutation of ARID1A in
molecular subtypes of gastric cancer / K. Wang, J. Kan, S.T. Yuen // Nat Genet. – 2011.–
Vol. 43. – P. 1219–1223.
188. Wang, L. Correlation between the methylation of SULF2 and WRN
promoter and the irinotecan chemosensitivity in gastric cancer / K. Wang, S.T. Yuen, J.
Xu // BMC Gastroenterol. – 2013. – Vol. 13. – P. 173.
189. Wattanawongdon, W. Expression of Matrix Metalloproteinase–7 Predicts
Poor Prognosis in Gastric Cancer / W. Wattanawongdon // Biomed Res Int. – 2022. – P.
25–34.
190. Digestive System Tumours. WHO Classification of Tumours, 5th Edition,
Volume 1. – WHO Classification of Tumours Editorial Board, 2019.
191. Wu, X. An overview of the multifaceted roles of miRNAs in gastric cancer:
Spotlight on novel biomarkers and therapeutic targets / X. Wu // Biochem Pharmacol. –
2019. – Vol. 163. – P. 425–439.
192. Xi, Y. Helicobacter pylori regulates stomach diseases by activating cell
pathways and DNA methylation of host cells / Y. Hi // Front Cell Dev Biol. – 2023. –
Vol. 11.
193. Xie, J. MiR374b–5p suppresses RECK expression and promotes gastric
cancer cell invasion and metastasis / J. Xie // World J. Gastroenterol. – 2014. – Vol. 20
(46). – P. 17439–17447.
194. Yamada, T. The survival difference between gastric cancer patients from the
UK and Japan re–mains after weighted propensity score analysis considering all back–
ground factors / T.Yamada // Gastric Cancer. – 2016. – Vol. 19(2). – P. 479–489. –
https://doi.org/10.1007/s10120–015–0480–5.
195. Yan, C. Drugging the undruggable: transcription therapy for cancer / C. Yan
C, P.J. Higgins // Biochim Biophys Acta. – 2013. – Vol. 1835. – P. 76–85.
https://t.me/med1917
207
196. Yao, F. Recurrent fusion genes in gastric cancer: CLDN18–ARHGAP26
induces loss of epithelial integrity / F. Yao, J.P. Kausalya, Y.Y. Sia // Cell Rep. – 2015.
– Vol. 12. – P. 272–85.
197. Yeh, Y.C. Elevated serum matrix metalloproteinase–3 and –7 in H. Pylori–
related gastric cancer can be biomarkers correlating with a poor survival / E.C. Yeh //
Digestive Diseases and Sciences. – 2010. – Vol. 55(6). – P. 1649–1657.
198. Yin, Y. Helicobacter pylori potentiates epithelial: mesenchymal transition in
gastric cancer: links to soluble HB–EGF, gastrin and matrix metalloproteinase–7 / Y. Yin,
A.M. Grabowska, P.A. Clarke // Gut. – 2010. – Vol. 59(8). – P. 32–45.
199. Zhang, L. Genome–wide analysis of histone H3 lysine 27 trimethylation by
ChIP–chip in gastric cancerpatients / L. Zhang, K. Zhong, Y. Dai // J Gastroenterol. –
2009. – Vol. 44. – P. 305–312.
200. Zhang, Y. Coexpression of Matrix Metalloproteinase–7 and Tissue Inhibitor
of Metalloproteinase–1 as a Prognostic Biomarker in Gastric Cancer / Y. Zhang // Dis
Markers. – 2020.
201. Zheng, H. C. Mixed–type gastric carcinomas exhibit more aggressive fea–
tures and indicate the histogenesis of carcinomas / H.C. 176. Zheng // Virchows Arch. –
2008. – Vol. 452(5). – P. 525–534. – URL: https://doi.org/10.1007/s00428–007–0572–7
(Accessed: 14.11.2023).
202. Zhou, Z. Expression of Wnt3, β–catenin and MMP–7 in gastric cancer and
precancerous lesions and their correlations with Helicobacter pylori infection / Z. Zhou,
G. Ye, J. Peng // Yi Xue Ban. – 2021. – Vol. 46(6). – P. 575–582.
https://t.me/med1917
Соседние файлы в папке Библиотека им академика М.И. Перельмана